QTTB — Q32 Bio Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1661998 ·
Last close
$8.09
Market Cap
$240.83M
52W High
$23.57
52W Low
$1.90
ADV30
959,097
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -9,118,000 | -8,946,000 | 115,867,000 | 106,270,000 | 9,962,000 |
| Mar 2026 | 0 | — | -7,722,000 | -7,609,000 | 63,675,000 | 50,751,000 | 17,362,000 |
| Dec 2025 | 53,737,000 | — | 45,879,000 | 57,730,000 | 61,776,000 | 48,297,000 | 19,762,000 |
| Sep 2025 | 0 | — | -7,577,000 | -7,389,000 | 57,784,000 | 49,039,000 | 76,232,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-19,828,000
Investing CF
$7,000,000
Financing CF
$64,266,000
CapEx
$-2,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.36
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-221,548,000
Inventory
—
Receivables
$2,392,000
ST Investments
—
EBIT TTM
$34,001,000
Pretax Income TTM
$33,786,000
Interest Exp TTM
$1,100,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$53,737,000
EBITDA
$21,818,000
Free Cash Flow
$19,392,250
Enterprise Value
$229,467,072
Total Cash
$106,270,000
Total Debt
$5,296,000
Shares Out
29,769,466
Trailing EPS
$3.14
Book Value
$4.46
ROE
72.1%
ROA
14.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 53,737,000 | 16,902,000 | 29,821,000 | 61,776,000 | 19,762,000 | 42,014,000 | -33,543,000 |
| Dec 2024 | 0 | -66,102,000 | -47,733,000 | 92,332,000 | 86,657,000 | 5,675,000 | -67,715,000 |
| Dec 2023 | -6,651,000 | -48,255,000 | -53,743,000 | 47,057,000 | 229,978,000 | -182,921,000 | -18,677,000 |
| Dec 2022 | 6,651,000 | -39,225,000 | -42,809,000 | 61,774,000 | 192,486,000 | -130,712,000 | -10,957,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$53,737,000
NetIncome TTM
$33,243,000
OpCashFlow TTM
—
Assets (Latest)
$63,675,000
Forward EPS
$-1.02
Max Pain — expiry 2026-10-16
max pain strike: $10.00 · spot: $8.09 · call oi: 1,687 · put oi: 208
Expected Move to 2026-10-16:
±$1.10
(13.60%) —
implied range
$6.99 –
$9.19
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMRX | Immuneering Corp | $241.97M | $3.74 | — |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | $243.40M | $6.43 | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $237.63M | $2.51 | — |
| SIGA | SIGA TECHNOLOGIES INC | $235.67M | $3.28 | — |
| VCRE | Vicore Pharma Holding AB | $248.41M | $8.82 | — |
News headlines (Yahoo Finance, 1h cache)
Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026
2026-09-30 13:15 · Yahoo
Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Co
2026-09-21 13:15 · Yahoo
Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer
2026-09-14 10:59 · Yahoo
Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround
2026-09-07 13:35 · Yahoo
Q32 Bio to Participate in Upcoming September Investor Conferences
2026-09-01 10:59 · Yahoo
Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
2026-08-17 13:55 · Yahoo
Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice
2026-07-20 16:00 · Yahoo
Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
2026-07-15 13:55 · Yahoo
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
2026-07-15 02:58 · Yahoo
Q32 Bio stock surges 83% on positive alopecia drug trial data
2026-07-14 13:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.